FDA gives green light to easy-to-use infusion tech that helps manage motor symptoms without surgery

Great news for people with Parkinson’s in the U.S. — the FDA has just approved a new way to deliver apomorphine, a medication used to manage movement symptoms in advanced Parkinson’s disease. And the best part? No surgery is needed. This treatment uses a device called the Neria™ Guard, made by the medical technology company Convatec. Already widely used in Europe, it’s now been approved in the U.S. for continuous, under-the-skin (subcutaneous) delivery of apomorphine — offering a practical alternative to more invasive procedures like brain surgery or deep brain stimulation. 🧠 What is Apomorphine, and Why is This a Big Deal? Apomorphine is a dopamine agonist, a type of medication that mimics the effects of dopamine in the brain. It’s especially helpful in managing “off” times — those frustrating periods when other Parkinson’s medications wear off, and symptoms like slowness, stiffness, or tremor return. Traditionally, apomorphine has been given either as an injection or through devices that can be fiddly or hard to use. But now, the Neria™ Guard infusion set makes it easier than ever to receive a steady dose of the medication throughout the day — all via a small, wearable pump. This means: No more repeated injections No invasive surgery Fewer ups and downs in symptom control More independence and better quality of life 🩹 So, What Is the Neria™ Guard? Think of it as a clever infusion set with a button. With just one touch, the device inserts a tiny, soft tube just under the skin. It connects to a small external pump that delivers medication continuously — helping keep symptoms more stable throughout the day. Key features include: Automatic, retractable needle for comfortable, safer insertion Fewer user errors thanks to intuitive design Designed for home use, so people can manage their treatment without relying on a clinic Already trusted in Europe, now expanding to the U.S. Over 1 million people worldwide already use Convatec infusion sets for different health conditions, including Parkinson’s, diabetes, and chronic pain. 🇺🇸 Why This Matters in the U.S. — and Globally The number of people diagnosed with Parkinson’s in the U.S. is rising fast. It’s now the second most common neurodegenerative disease, affecting over 1 million Americans. That number is expected to grow to 1.2 million by 2030. With nearly 90,000 new cases each year, having more treatment choices is critical — especially those that can be used at home and don’t involve surgery. Although this FDA approval is for the U.S., innovations like this benefit people worldwide. Regulatory milestones often pave the way for: Wider access in other countries New investment in similar technology More research into user-friendly drug delivery In short, progress in one country often means hope for many more around the globe. 🗣 What Convatec Says “Having new treatment options is a big win for Parkinson’s patients and their families,” said Kjersti Grimsrud, President of Infusion Care at Convatec. “We’re proud to help give more independence to people to live their daily lives.” 🧪 Final Thoughts This new FDA approval marks a big step forward in Parkinson’s care — showing that technology can be a powerful ally in making treatments easier, safer, and more empowering. While this isn’t a cure, it’s another tool in the toolbox to help people manage symptoms better, stay independent longer, and feel more in control of daily life. We’ll keep you updated as it becomes available through Convatec’s partners in the U.S. — and potentially beyond.